이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

CTSN 색전증 보호 시험 (EMPRO)

2026년 10월 1일 업데이트: Annetine Gelijns, Icahn School of Medicine at Mount Sinai

고위험 판막 수술을 받는 환자의 색전 보호

This is a prospective, multi-center, randomized effectiveness trial of the CardioGard Embolic Protection Cannula in high-risk valve surgery patients.

연구 개요

상세 설명

This is a prospective, multicenter, randomized controlled clinical trial that will evaluate the effectiveness and safety of the CardioGard embolic protection cannula compared to a standard cannula. The enrollment period is expected to last 30 months, and all patients will be followed for 12 months post procedure.

RANDOMIZATION Patients will be randomized 1:1 to the embolic protection device or to a standard cannula in the operating room (OR) immediately after sternotomy and confirmation by the surgical team of the patient's suitability for the proposed intervention (CardioGard embolic protection device). Randomization will be with equal allocation and stratified by site and by procedure (i.e., isolated valve surgery or combined procedures, such as double valve or valve plus coronary artery bypass grafting, CABG). The randomization assignment will be controlled centrally and performed through a web-based data collection system that automates the delivery of the randomization codes. From the point of treatment assignment, primary efficacy will be analyzed by intention-to-treat; that is, the patients will be grouped by their assignments at randomization regardless of whether or not they actually received the treatment to which they were assigned.

STUDY POPULATION The patient population for this trial consists of patients age ≥ 60 undergoing different types of valve surgery with or without CABG via full or minimal-access sternotomy using legally marketed valve(s). Specific inclusion and exclusion criteria are listed below. All patients who meet the eligibility criteria may be included in the study regardless of gender, race, or ethnicity.

SUBSTUDY Sleep Disturbance Ancillary Sub-Study - Patients undergoing surgery for valvular heart disease (VHD) are at high risk for adverse events, including high rates of post-operative delirium (POD). Should circadian disruption be found to be an important predictor in this high-risk population, safe, low cost, and easy to administer therapies to regulate circadian rhythm such as light therapy could be evaluated in future studies

The aims of this ancillary sub-study include:

  1. To investigate the association between short sleep duration, less sleep regularity, and greater circadian rhythm disruption prior to surgery and POD within 7 days of VHD surgery.
  2. To investigate the association between short sleep duration, less sleep regularity and greater circadian rhythm disruption (reduced melatonin and cortisol amplitudes) after surgery and POD within 7 days of VHD surgery.

Approximately 300 EMPRO trial participants will be enrolled into the ancillary study. The study is being conducted in highly experienced clinical centers in the U.S. and Canada. The estimated enrollment period is 12-15 months.

All eligible and consented patients in the parent EMPRO trial will be offered enrollment in this ancillary study through the parent trial consent process.

연구 유형

중재적

등록 (추정된)

842

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Arkansas
      • North Little Rock, Arkansas, 미국, 72117
        • CHI St. Vincent Heart Institute
    • California
      • Los Angeles, California, 미국, 90033
        • Keck Hospital of the University of Southern California
    • Georgia
      • Atlanta, Georgia, 미국, 30322
        • Emory University
    • Louisiana
      • New Orleans, Louisiana, 미국, 70506
        • Ochsner Clinic
    • Maine
      • Portland, Maine, 미국, 04102
        • Maine Medical Center
    • Maryland
      • Baltimore, Maryland, 미국, 21287
        • Johns Hopkins Medicine
      • College Park, Maryland, 미국, 20742
        • University of Maryland
    • Massachusetts
      • Boston, Massachusetts, 미국, 02114
        • Massachusetts General Hospital
    • Michigan
      • Ann Arbor, Michigan, 미국, 48109
        • University of Michigan
    • Minnesota
      • Rochester, Minnesota, 미국, 55905
        • Mayo Clinic
    • Missouri
      • Kansas City, Missouri, 미국, 64111
        • Saint Luke's Hospital of Kansas City
    • New York
      • New York, New York, 미국, 10032
        • Columbia University Medical Center
      • New York, New York, 미국, 21287
        • Northwell Health
      • The Bronx, New York, 미국, 10467
        • Montefiore Medical Center
    • North Carolina
      • Durham, North Carolina, 미국, 27710
        • Duke University
    • Ohio
      • Cincinnati, Ohio, 미국, 45267
        • University of Cincinnati Medical Center
      • Cleveland, Ohio, 미국, 44195
        • Cleveland Clinic
    • Pennsylvania
      • Philadelphia, Pennsylvania, 미국, 19104
        • Hospital of the University of Pennsylvania
    • Virginia
      • Charlottesville, Virginia, 미국, 22903
        • University of Virginia
    • West Virginia
      • Morgantown, West Virginia, 미국, 26506
        • West Virginia University
    • Ontario
      • London, Ontario, 캐나다
        • London Health Sciences Centre
      • Ottawa, Ontario, 캐나다
        • University of Ottawa Heart Institute
    • Quebec
      • Montreal, Quebec, 캐나다
        • Montreal Heart Institute
      • Québec, Quebec, 캐나다, QC G1V 4G5
        • Hôpital Laval

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

60년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Age ≥ 60 years

  • Planned de novo or redo:

    • Surgical aortic valve replacement SAVR ± ascending aortic repair (if circulatory arrest is not required) ± CABG
    • Mitral valve replacement (MVR) ± CABG
    • Mitral Valve Repair + CABG,
    • Double/Triple valve surgery ± CABG; Ross procedure These procedures can be done via a full or minimal-access sternotomy (using central aortic perfusion cannulae) with legally marketed valve(s), and can be done in combination with an left atrial appendage (LAA) closure/excision or partial/complete Maze procedure.
    • Valve sparing aortic root replacement (David procedure)
    • Valve sparing aortic root replacement (David procedure)
  • No evidence of neurological impairment as defined by a NIHSS ≤1 and modified Rankin scale (mRS) ≤2 within 30 days prior to randomization

  • Ability to provide informed consent and comply with the protocol

Exclusion Criteria:

  • History of clinical stroke within 3 months prior to randomization
  • Cerebral and or aortic arch arteriography or interventions within 3 days of the planned procedure
  • Coronary catheterization within 3 days of index procedure, and the required repeat NIHSS score post-catheterization is worse than the screening/baseline NIHSS score conducted prior to the catheterization
  • Active endocarditis at time of randomization with vegetation criteria
  • Clinical signs of cardiogenic shock or treatment with IV inotropic therapy prior to randomization
  • Participation in an interventional (drug or device) trial
  • Isolated mitral valve repair, isolated tricuspid valve repair or combined mitral valve repair and tricuspid valve repair
  • Anticipated requirement for prolonged mechanical ventilation greater than 48 hours after surgery in the opinion of the investigator
  • Planned concomitant carotid endarterectomy during index surgical procedure

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 방지
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 하나의

무기와 개입

참가자 그룹 / 팔
개입 / 치료
활성 비교기: CardioGard Embolic Protection Cannula

In patients assigned to the embolic protection device group, the CardioGard Embolic Protection Cannula is used instead, according to the manufacturer's instructions for use (IFU).

The CardioGard embolic protection cannula is a device that combines the function of a standard aortic cannula with an added suction mechanism to capture debris that may result from cardiac surgery. The device is comprised of 2 hollow tubes. The first tube is the standard main forward-flow tube to return oxygenated blood to the patient's aorta. The second tube attached to an existing bypass vent port, is a novel element located posteriorly to the main tube; its function is to facilitate blood and particle suction by directing the blood back to the reservoir of the coronary bypass machine, while the retrieved embolic debris is eliminated through the filter of the venous reservoir.

위약 비교기: Standard Aortic Cannula

In patients assigned to the standard cannula group, standard cannulation techniques are performed using any standard aortic cannula of the surgeon's choice

An aortic cannula is a device that is used routinely during cardiac surgery to return oxygenated blood from the cardiac bypass machine into the patient's aorta.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Number of patients who experience ischemic stroke and Acute Kidney Injury (AKI)
기간: within 3 days post-randomization

The combined number of patients who experience clinical ischemic strokes and acute kidney injuries that have occurred within 3 days post-randomization.

within 3 days post-randomization
Number of patients who experience of death and delirium
기간: by 7 days post-randomization

The combined number of patients who experience death and delirium by 7 days post-randomization (with a blanking period for delirium of days 1 and 2 post-operatively).

by 7 days post-randomization

2차 결과 측정

결과 측정
측정값 설명
기간
Proportion of patients who experience a clinical ischemic stroke
기간: within 3 days post-randomization

The proportion of patients who experience a clinical ischemic stroke within 3 days will be compared between the two groups (i.e., standard cannula versus the CardioGard device).

within 3 days post-randomization
Proportion of patients who experience a clinical ischemic stroke
기간: within 7 days post-randomization

The proportion of patients who experience a clinical ischemic stroke within 7 days will be compared between the two groups (i.e., standard cannula versus the CardioGard device).

within 7 days post-randomization
Number of patients with disabling clinical stroke
기간: within 3 days post-randomization

Number of patients with disabling clinical stroke within 3 days post-randomization

within 3 days post-randomization
Number of patients with disabling clinical stroke
기간: within 7 days post-randomization

Number of patients with disabling clinical stroke within 7 days post-randomization

within 7 days post-randomization
Neurological outcomes assessed by National Institutes of Health Stroke Scale (NIHSS)
기간: within 3 days post-randomization

Neurological outcomes are assessed by National Institutes of Health stroke Scale (NIHSS) to compare the treatment outcomes of three types of service delivery models. The NIHSS is an 11-item impairment scale to evaluate neurologic outcome and degree of recovery.

Each item is scored between 0 and up to 4, total score ranges 0 (normal function) and a maximum possible score 42, with higher score indicating higher level of impairment.

These assessments will be administered by blinded neurology trainees or study coordinators who are certified to administer the assessments.

within 3 days post-randomization
Neurological outcomes assessed by National Institutes of Health Stroke Scale (NIHSS)
기간: within 7 days post-randomization

Neurological outcomes are assessed by National Institutes of Health stroke Scale (NIHSS) to compare the treatment outcomes of three types of service delivery models. The NIHSS is an 11-item impairment scale to evaluate neurologic outcome and degree of recovery.

Each item is scored between 0 and up to 4, total score ranges 0 (normal function) and a maximum possible score 42, with higher score indicating higher level of impairment.

These assessments will be administered by blinded neurology trainees or study coordinators who are certified to administer the assessments.

within 7 days post-randomization
Number of patients with disabling clinical stroke determined by modified Rankin Scale (mRS) score ≥2
기간: at baseline

Number of patients with disabling clinical stroke as indicated by mRS score ≥2. mRS will be assessed at baseline days.

The scale runs from 0-6, running from perfect health without symptoms to death. A higher score indicates greater impairment.

0 - No symptoms.

  1. - No significant disability. Able to carry out all usual activities, despite some symptoms.
  2. - Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.

3. - Moderate disability. Requires some help, but able to walk unassisted. 4 - Moderately severe disability. Unable to walk and attend own bodily needs without assistance.

5 - Severe disability. Requires constant nursing care and attention, bedridden, incontinent.

6 - Dead.

at baseline
Number of patients with disabling clinical stroke determined by modified Rankin Scale (mRS) score ≥2
기간: at 30 days

Number of patients with disabling clinical stroke as indicated by mRS score ≥2. mRS will be assessed at 30 days.

The scale runs from 0-6, running from perfect health without symptoms to death. A higher score indicates greater impairment.

0 - No symptoms.

  1. - No significant disability. Able to carry out all usual activities, despite some symptoms.
  2. - Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.

3. - Moderate disability. Requires some help, but able to walk unassisted. 4 - Moderately severe disability. Unable to walk and attend own bodily needs without assistance.

5 - Severe disability. Requires constant nursing care and attention, bedridden, incontinent.

6 - Dead.

at 30 days
Number of patients with disabling clinical stroke determined by modified Rankin Scale (mRS) score ≥2
기간: at 90 days

Number of patients with disabling clinical stroke as indicated by mRS score ≥2. mRS will be assessed at 90 days.

The scale runs from 0-6, running from perfect health without symptoms to death. A higher score indicates greater impairment.

0 - No symptoms.

  1. - No significant disability. Able to carry out all usual activities, despite some symptoms.
  2. - Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.

3. - Moderate disability. Requires some help, but able to walk unassisted. 4 - Moderately severe disability. Unable to walk and attend own bodily needs without assistance.

5 - Severe disability. Requires constant nursing care and attention, bedridden, incontinent.

6 - Dead.

at 90 days
Montreal Cognitive Assessment (MoCA) Score
기간: at baseline

Global cognitive screening performance will be compared between groups and collected via the Montreal Cognitive Assessment (MoCA) - blind version at presurgical baseline.

The MoCA scale is used for detecting cognitive impairment. The scores range between 0 to 30 points; a score of 26 or above was considered normal. Higher values represent a better outcome.

at baseline
Montreal Cognitive Assessment (MoCA) Score
기간: at 90 days

Global cognitive screening performance will be compared between groups and collected via the Montreal Cognitive Assessment (MoCA) - blind version at 90 days.

The MoCA scale is used for detecting cognitive impairment. The scores range between 0 to 30 points; a score of 26 or above is considered normal. Higher values represent a better outcome.

at 90 days
Montreal Cognitive Assessment (MoCA) Score
기간: at 12 months

Global cognitive screening performance will be compared between groups and collected via the Montreal Cognitive Assessment (MoCA) - blind version at 12 months.

The MoCA scale is used for detecting cognitive impairment. The scores range between 0 to 30 points; a score of 26 or above is considered normal. Higher values represent a better outcome.

at 12 months
Oral Trail Making Test - Parts A and B (executive function)
기간: at baseline

The Trail Making Test consists of 25 circles distributed over a sheet of paper. In Part A, the circles are numbered 1 - 25, and the patient should draw lines to connect the numbers in ascending order. In Part B, the circles include both numbers (1 - 13) and letters (A - L); as in Part A, the patient draws lines to connect the circles in an ascending pattern, but with the added task of alternating between the numbers and letters (i.e., 1-A-2-B-3-C, etc.). The patient should be instructed to connect the circles as quickly as possible, without lifting the pen or pencil from the paper. Time the patient connects the "trail." If the patient makes an error, point it out immediately and allow the patient to correct it. Results for part B are reported as the number of seconds required to complete the task; therefore, higher scores reveal greater impairment.

at baseline
Oral Trail Making Test - Parts A and B (executive function)
기간: at 90 days post-randomization

The Trail Making Test consists of 25 circles distributed over a sheet of paper. In Part A, the circles are numbered 1 - 25, and the patient should draw lines to connect the numbers in ascending order. In Part B, the circles include both numbers (1 - 13) and letters (A - L); as in Part A, the patient draws lines to connect the circles in an ascending pattern, but with the added task of alternating between the numbers and letters (i.e., 1-A-2-B-3-C, etc.). The patient should be instructed to connect the circles as quickly as possible, without lifting the pen or pencil from the paper. Time the patient connects the "trail." If the patient makes an error, point it out immediately and allow the patient to correct it. Results for part B are reported as the number of seconds required to complete the task; therefore, higher scores reveal greater impairment.

at 90 days post-randomization
Oral Trail Making Test - Parts A and B (executive function)
기간: at 12 months post-randomization

The trail Making Test consist of 25 circles distributed over a sheet of paper. In Part A, the circles are numbered 1 - 25, and the patient should draw lines to connect the numbers in ascending order. In Part B, the circles include both numbers (1 - 13) and letters (A - L); as in Part A, the patient draws lines to connect the circles in an ascending pattern, but with the added task of alternating between the numbers and letters (i.e., 1-A-2-B-3-C, etc.). The patient should be instructed to connect the circles as quickly as possible, without lifting the pen or pencil from the paper. Time the patient connects the "trail." If the patient makes an error, point it out immediately and allow the patient to correct it. Results for part B are reported as the number of seconds required to complete the task; therefore, higher scores reveal greater impairment.

at 12 months post-randomization
Wechsler Adult Intelligence Scale-Revised (WAIS-R) Digit Span (auditory-verbal attention)
기간: baseline

The WAIS-R Digit Span test assesses short term or working memory. The examinee listens to sequences of numbers orally and then repeats them as heard, in increasing order, and in reverse order. The raw scores for "digit span" range from a minimum of 2 to a maximum of 8. For this test, the longer the span the better the cognition; therefore, the higher score is the better outcome.

baseline
Wechsler Adult Intelligence Scale-Revised (WAIS-R) Digit Span (auditory-verbal attention)
기간: at 90 days post-randomization

The WAIS-R Digit Span test assesses short term or working memory. The examinee listens to sequences of numbers orally and then repeats them as heard, in increasing order, and in reverse order. The raw scores for "digit span" range from a minimum of 2 to a maximum of 8. For this test, the longer the span the better the cognition; therefore, the higher score is the better outcome.

at 90 days post-randomization
Wechsler Adult Intelligence Scale-Revised (WAIS-R) Digit Span (auditory-verbal attention)
기간: at 12 months post-randomization

The WAIS-R Digit Span test assesses short term or working memory. The examinee listens to sequences of numbers orally and then repeats them as heard, in increasing order, and in reverse order. The raw scores for "digit span" range from a minimum of 2 to a maximum of 8. For this test, the longer the span the better the cognition; therefore, the higher score is the better outcome.

at 12 months post-randomization
Wechsler Adult Intelligence Scale-Revised (WAIS-R) Digit Symbol Substitution Test (processing speed)
기간: at baseline

The WAIS-R Digit Symbol Substitution Test (DSST) is a paper-and-pencil cognitive test that consist of number-symbol pairs. It requires the examinee to copy, into spaces below rows of numbers, the symbols that are paired to each number. The DSST score is the number of digits coded correctly in a 90-second test period

at baseline
Delis-Kaplan Executive Function System (D-KEFS) Verbal Fluency Test (verbal fluency/executive function)
기간: at baseline

The D-KEFS Verbal Fluency Test is comprised of three testing conditions: Letter Fluency, Category Fluency, and Category Switching. This test measures multiple aspects of verbal productivity and cognitive flexibility. It evaluates effectiveness of novel and semantic search strategies, and assesses flexibility in the implementation of word search strategies. There are three conditions in the test in which the examinee must say as many words as they can by letter, category, and category switching prompts.

at baseline
Delis-Kaplan Executive Function System (D-KEFS) Verbal Fluency Test (verbal fluency/executive function)
기간: at 90 days post-randomization

The D-KEFS Verbal Fluency Test is comprised of three testing conditions: Letter Fluency, Category Fluency, and Category Switching. This test measures multiple aspects of verbal productivity and cognitive flexibility. It evaluates effectiveness of novel and semantic search strategies, and assesses flexibility in the implementation of word search strategies. There are three conditions in the test in which the examinee must say as many words as they can by letter, category, and category switching prompts.

at 90 days post-randomization
Delis-Kaplan Executive Function System (D-KEFS) Verbal Fluency Test (verbal fluency/executive function)
기간: at 12 months post-randomization

The D-KEFS Verbal Fluency Test is comprised of three testing conditions: Letter Fluency, Category Fluency, and Category Switching. This test measures multiple aspects of verbal productivity and cognitive flexibility. It evaluates effectiveness of novel and semantic search strategies, and assesses flexibility in the implementation of word search strategies. There are three conditions in the test in which the examinee must say as many words as they can by letter, category, and category switching prompts.

at 12 months post-randomization
Incidence of Delirium
기간: first 7 days post-randomization

The incidence of delirium will be assessed daily by the Confusion Assessment Method (3D-CAM or CAM-ICU) scale, or by the presence of a delirium adverse event, during the first 7 days post-randomization.

The CAM consists of 4 features: 1-Onset, 2-Inattention, 3-Disorganized thinking, and 4-altered level of consciousness. The diagnosis of delirium by CAM is based on the presence of features 1 and 2, and either 3 or 4 and involves the presence/absence of delirium, but not its severity. Any error or behavioral observation consistent with a delirium feature means that feature is present.

first 7 days post-randomization
Duration of Delirium
기간: first 7 days post-randomization

The duration of delirium will be measured as the number of days with positive CAM assessments or delirium adverse events by 7 days post-randomization.

The CAM consists of 4 features: 1-Onset, 2-Inattention, 3-Disorganized thinking, and 4-altered level of consciousness. The diagnosis of delirium by CAM is based on the presence of features 1 and 2, and either 3 or 4.

first 7 days post-randomization
Severity of Delirium
기간: first 7 days post-randomization

The severity of delirium will be measured during daily screening using standardized algorithms for extracting symptom severity from the 3D-CAM and CAM-ICU.

first 7 days post-randomization
Number of Patients who experience Acute kidney injury (AKI)
기간: within -7 days post-randomization

Number of Patients who experience Acute kidney injury will be assessed within 7 days post-randomization.

within -7 days post-randomization
All-cause mortality
기간: within 90 days post-randomization

All-cause mortality within 90 days post-randomization will be assessed.

within 90 days post-randomization
All-cause mortality
기간: within 12 months post-randomization

All-cause mortality within 12-months post-randomization will be assessed.

within 12 months post-randomization
Length of Index Hospitalization
기간: at hospital discharge, up to 30 days

Overall length of stay for the index hospitalization post-randomization will be measured and broken down by days spent in the ICU versus days not in the ICU.

at hospital discharge, up to 30 days
Discharge disposition
기간: at hospital discharge, up to 30 days

Discharge disposition

at hospital discharge, up to 30 days
Readmissions rates
기간: first 90 days

Readmission rates will be calculated for the first 90 days following randomization. Hospitalizations will be classified for all causes including for cardiovascular readmissions.

first 90 days
Readmissions rates
기간: up to 1 year post-randomization

Readmission rates will be calculated for the duration of follow-up, out to 1 year. Hospitalizations will be classified for all causes including for cardiovascular readmissions.

up to 1 year post-randomization
Days Alive out of Hospital
기간: within 90 days post-randomization

Days alive out of hospital and nursing/rehab facilities within 90 days after randomization

within 90 days post-randomization
Actigraphy
기간: 7-day period prior to index surgical procedure and Day 1 post index surgical procedure through hospital discharge

Actigraphy data will be collected for a period of 7 days prior to the index surgical procedure. Actigraphic monitoring employs an accelerometer the size of a watch, which each study patient will wear on the wrist.

Collected for participants in substudy.

7-day period prior to index surgical procedure and Day 1 post index surgical procedure through hospital discharge
Amount of Circadian Light
기간: 7-day period prior to index surgical procedure

A Speck light meter will be worn as a pendant while awake for a period of 7 days prior to surgery. Light measurements from light meters used as pendants are the closest to light measurements at eye level. The light meter will also be used to monitor the total amount of circadian light received by the patient.

Collected for participants in substudy.

7-day period prior to index surgical procedure
Photopic Light Levels
기간: 7-day period prior to index surgical procedure

A Speck light meter will be worn as a pendant while awake for a period of 7 days prior to surgery. Light measurements from light meters used as pendants are the closest to light measurements at eye level. The light meter will also be used to calculate photopic light levels

Collected for participants in substudy.

7-day period prior to index surgical procedure
Circadian Stimulus Values
기간: 7-day period prior to index surgical procedure

A Speck light meter will be worn as a pendant while awake for a period of 7 days prior to surgery. Light measurements from light meters used as pendants are the closest to light measurements at eye level. The light meter will also be used to calculate circadian stimulus values,

Collected for participants in substudy.

7-day period prior to index surgical procedure
Richards-Campbell Sleep Questionnaire
기간: Day 1 post index surgical procedure through patient discharge from the ICU (average ICU stay is 3 days)

Patients who are able to do so will be asked to fill out the Richards-Campbell Sleep Questionnaire (RCSQ), which is a brief 2-minute questionnaire designed for patient use in the ICU. Full score range from 0-100, with higher score indicating better sleep.

Collected for participants in substudy.

Day 1 post index surgical procedure through patient discharge from the ICU (average ICU stay is 3 days)

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Annetine C. Gelijns, PhD, Icahn School of Medicine at Mount Sinai
  • 수석 연구원: Steve Messe, MD, University of Pennsylvania
  • 수석 연구원: Alexander Iribarne, MD, Northwell Health

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2023년 9월 18일

기본 완료 (추정된)

2027년 4월 1일

연구 완료 (추정된)

2027년 4월 1일

연구 등록 날짜

최초 제출

2023년 8월 21일

QC 기준을 충족하는 최초 제출

2023년 8월 31일

처음 게시됨 (실제)

2023년 9월 7일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 2일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 10월 1일

마지막으로 확인됨

2026년 10월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).

IPD 공유 기간

De-identified study data sets must be submitted to the designated NHLBI Program Official no later than 3 years after the end of the clinical activity (final patient follow-up, etc.) or 2 years after the main paper of the trial has been published, whichever comes first. Data are prepared by the study coordinating center and sent to the designated PO for review prior to release.

IPD 공유 액세스 기준

Anyone who wishes to access the data. Any purpose. Data are available indefinitely at (Link to be included in the URL field below).

IPD 공유 지원 정보 유형

  • 연구_프로토콜
  • 수액
  • ICF

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

예

미국에서 제조되어 미국에서 수출되는 제품

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다